Tseliou Eleni, Fouad Joseph, Reich Heidi, Slipczuk Leandro, de Couto Geoffrey, Aminzadeh Mark, Middleton Ryan, Valle Jackelyn, Weixin Liu, Marbán Eduardo
Cedars-Sinai Heart Institute, Los Angeles, California.
Harvard College, Boston, Massachusetts.
J Am Coll Cardiol. 2015 Aug 11;66(6):599-611. doi: 10.1016/j.jacc.2015.05.068.
Cardiosphere-derived cells mediate therapeutic regeneration in patients after myocardial infarction and are undergoing further clinical testing for cardiomyopathy. The beneficial effects of cardiosphere-derived cells are mediated by the secretion of exosomes and possibly other extracellular membrane vesicles (EMVs).
This study sought to investigate the effect of cardiosphere-derived EMVs (CSp-EMVs) on fibroblasts in vitro and tested whether priming with CSp-EMVs could confer salutary properties on fibroblasts in vivo.
CSp-EMVs were isolated from serum-free media conditioned for 3 days by cardiospheres. Dermal fibroblasts were primed with CSp-EMVs for 24 h followed by exosomal micro-ribonucleic acid profiling. In vivo, we injected CSp-EMV-primed or -unprimed dermal fibroblasts (or CSp-EMVs) in a chronic rat model of myocardial infarction and defined the functional and structural consequences.
CSp-EMVs amplified their own biological signals: exposure of "inert" fibroblasts to CSp-EMVs rendered the fibroblasts therapeutic. Intramyocardially injected CSp-EMV-primed (but not unprimed) fibroblasts increased global pump function and vessel density while reducing scar mass. CSp-EMV priming caused fibroblasts to secrete much higher levels of stromal-cell-derived factor 1 and vascular endothelial growth factor and dramatically changed the micro-ribonucleic acid profile of fibroblast-secreted EMVs in vitro. The priming was followed by significant angiogenic and cardioprotective effects.
CSp-EMVs alter fibroblast phenotype and secretome in a salutary positive-feedback loop. The phenotypic conversion of inert cells to therapeutically active cells reveals a novel mechanism for amplification of exosome bioactivity.
心肌球衍生细胞可介导心肌梗死后患者的治疗性再生,目前正针对心肌病进行进一步的临床试验。心肌球衍生细胞的有益作用是由外泌体以及可能的其他细胞外膜泡(EMV)的分泌介导的。
本研究旨在调查心肌球衍生的EMV(CSp-EMV)对体外成纤维细胞的影响,并测试用CSp-EMV预处理是否能赋予体内成纤维细胞有益特性。
从心肌球在无血清培养基中培养3天的条件培养基中分离CSp-EMV。用CSp-EMV预处理真皮成纤维细胞24小时,随后进行外泌体微小核糖核酸谱分析。在体内,我们在慢性心肌梗死大鼠模型中注射经CSp-EMV预处理或未预处理的真皮成纤维细胞(或CSp-EMV),并确定其功能和结构后果。
CSp-EMV增强了自身的生物学信号:将“惰性”成纤维细胞暴露于CSp-EMV可使成纤维细胞具有治疗作用。心肌内注射经CSp-EMV预处理(而非未预处理)的成纤维细胞可提高整体泵功能和血管密度,同时减少瘢痕质量。CSp-EMV预处理使成纤维细胞分泌更高水平的基质细胞衍生因子1和血管内皮生长因子,并在体外显著改变成纤维细胞分泌EMV的微小核糖核酸谱。预处理后产生了显著的血管生成和心脏保护作用。
CSp-EMV通过有益的正反馈回路改变成纤维细胞表型和分泌组。惰性细胞向具有治疗活性细胞的表型转化揭示了外泌体生物活性放大的新机制。